<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01104220</url>
  </required_header>
  <id_info>
    <org_study_id>201102127</org_study_id>
    <nct_id>NCT01104220</nct_id>
  </id_info>
  <brief_title>Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk</brief_title>
  <official_title>Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about how the body stores fat in and around organs&#xD;
      (for example in the liver) and why this affects some people's health more than others.&#xD;
      Understanding this may lead to better treatments for diseases such as diabetes and&#xD;
      cardiovascular disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the specific cellular and organ system metabolic&#xD;
      and immunologic alterations that are associated with insulin resistance and inflammation in&#xD;
      order to identify putative mechanisms and novel bio-markers involved in the pathogenesis and&#xD;
      progression of inflammatory and cardiometabolic diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2010</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>Baseline</time_frame>
    <description>Insulin sensitivity assessed in vivo by using a hyperinsulinemic-euglycemic clamp procedure with stable isotope tracer infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>Baseline</time_frame>
    <description>TNF-alpha is a marker of inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 (IL-6)</measure>
    <time_frame>Baseline</time_frame>
    <description>Interleukin-6 is a marker of inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver tissue inflammation</measure>
    <time_frame>Baseline</time_frame>
    <description>Liver immune cell content</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal adipose tissue inflammation</measure>
    <time_frame>Baseline only in participants scheduled for bariatric surgery</time_frame>
    <description>Subcutaneous, omental and transverse mesocolic adipose tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal adipose tissue inflammation</measure>
    <time_frame>Baseline only in participants scheduled for gallbladder, inguinal hernia, hysterectomy or myomectomy surgery</time_frame>
    <description>Subcutaneous and omental adipose tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper vs lower adipose tissue inflammation</measure>
    <time_frame>Baseline (All groups)</time_frame>
    <description>Immune cell content in abdominal and femoral subcutaneous adipose tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exosome-mediated intercellular signaling</measure>
    <time_frame>Baseline only in participants scheduled for bariatric surgery</time_frame>
    <description>Signaling between cells and organs will be examined by isolating exosomes (small extracellular vesicles) from blood, subcutaneous, omental and transverse mesocolic adipose tissue and liver.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exosome-mediated intercellular signaling</measure>
    <time_frame>Baseline only in participants scheduled for gallbladder, inguinal hernia, hysterectomy or myomectomy surgery</time_frame>
    <description>Signaling between cells and organs will be examined by isolating exosomes (small extracellular vesicles) from blood, subcutaneous and omental adipose tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exosome-mediated intercellular signaling</measure>
    <time_frame>Baseline only in all participants</time_frame>
    <description>Signaling between cells and organs will be examined by isolating exosomes (small extracellular vesicles) from blood and abdominal and femoral subcutaneous adipose tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exosome-mediated intercellular signaling</measure>
    <time_frame>Before and after 20-30% weight loss (~3-4 months) in participants scheduled for bariatric surgery</time_frame>
    <description>Signaling between cells and organs will be examined by isolating exosomes (small extracellular vesicles) from blood and adipose tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic PNPLA3 synthesis rate</measure>
    <time_frame>Baseline only in people scheduled for gallbladder or bariatric surgery with I148I or M148M PNPLA3 variant</time_frame>
    <description>Synthesis rates assessed by stable isotope techniques in the fasted vs the fed states</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Metabolically Abnormal Obesity</condition>
  <condition>Metabolically Normal Obesity</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Lean, metabolically normal</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects with body mass index 18.5 - 24.9 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese, metabolically normal</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects with body mass index ≥30.0 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese, metabolically abnormal</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects with body mass index ≥30.0 kg/m² and impaired fasting or oral glucose tolerance and increased liver fat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese, scheduled for bariatric surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with a body mass index ≥35.0 kg/m² undergoing bariatric surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese, scheduled for gallbladder surgery</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects with a body mass index ≥35.0 kg/m² undergoing gallbladder surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean, scheduled for inguinal hernia, hysterectomy or myomectomy surgery</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects with body mass index 18.5 - 24.9 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Weight loss</intervention_name>
    <description>Bariatric surgery-induced weight loss to achieve ~20%-30% reduction in initial body weight</description>
    <arm_group_label>Obese, scheduled for bariatric surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Lean, metabolically healthy group - Body mass index (BMI) 18.5-24.9 kg/m2, HbA1C ≤5.6%,&#xD;
        fasting plasma glucose concentration &lt;100 mg/dl, 2-h OGTT plasma glucose concentration &lt;140&#xD;
        mg/dl and intrahepatic triglyceride (IHTG) content ≤5%.&#xD;
&#xD;
        Obese, metabolically healthy group - BMI ≥30 kg/m2, HHbA1C ≤5.6%, fasting plasma glucose&#xD;
        concentration &lt;100 mg/dl, 2-h OGTT plasma glucose concentration &lt;140 mg/dl and intrahepatic&#xD;
        triglyceride (IHTG) content ≤5%.&#xD;
&#xD;
        Obese, metabolically healthy group - BMI ≥30 kg/m2, IHTG content ≥5.6% and HbA1C ≥5.7% or&#xD;
        fasting plasma glucose concentration ≥100 mg/dl or 2-h OGTT plasma glucose concentration&#xD;
        ≥140 mg/dl.&#xD;
&#xD;
        Lean, scheduled for inguinal hernia, hysterectomy or myomectomy surgery - BMI 18.5-24.9&#xD;
        kg/m2, HbA1C ≤5.6%, fasting plasma glucose concentration &lt;100 mg/dl, 2-h OGTT plasma&#xD;
        glucose concentration &lt;140 mg/dl and IHTG content ≤5%.&#xD;
&#xD;
        Obese, scheduled for bariatric and gallbladder surgery - BMI ≥35.0kg/m2&#xD;
&#xD;
        Obese, scheduled for bariatric and gallbladder surgery (subgroup) - BMI ≥35.0kg/m2 with&#xD;
        either the I148I or the M148M variant for the PNPLA3 SNP rs738409.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active or previous history of liver diseases other than NAFLD&#xD;
&#xD;
          -  history of alcohol abuse&#xD;
&#xD;
          -  currently consuming ≥20 g alcohol/day&#xD;
&#xD;
          -  severe hypertriglyceridemia (&gt;300 mg/dL)&#xD;
&#xD;
          -  smoke tobacco&#xD;
&#xD;
          -  cancer diagnosis within the previous 5 years&#xD;
&#xD;
          -  medications that might confound the study results&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  exercise &gt;2 h/week&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Klein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Henk</last_name>
    <phone>314-362-8250</phone>
    <email>bhenk@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>Obesity</keyword>
  <keyword>Metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

